Abstract

The receptor tyrosine kinase Tie-2 is involved in vessel remodeling and maturation, and has been regarded as a potential target for the treatment of various solid tumors. The absence of novel, potent and selective inhibitors severely hampers the understanding of the therapeutic potential of Tie-2. In the present work, we describe the discovery of novel type-I inhibitors of Tie-2 by structure-based virtual screening. Preliminary SAR was also performed based on one active compound, and several novel inhibitors with low micro-molar affinity were discovered. To directly compare the efficiency between different filtering strategies in selecting VS candidates, two methods were separately carried out to screen the same chemical library, and the selected VS candidates were then experimentally assessed by in vitro enzymatic assays. The results demonstrate that the hit rate is improved when stricter drug-likeness criteria and less number of molecules for clustering analysis are used, and meanwhile, the molecular diversity of the compounds still maintains. As a case study of TIE-2, the information presented in this work underscores the importance of selecting an appropriate selection strategy in VS campaign, and the novel inhibitors identified and the detailed binding modes of action provide a starting point for further hit-to-lead optimization process.

Highlights

  • Targeting VEGF signaling have been under clinical assessment, and several of them, such as sunitinib (Sutent) and sorafenib (Nexavar), have been approved by the Food and Drug Administration (FDA)[4,9,10]

  • We can find that the p values for 3L8P are much lower than those for 2WQB and the AUC values from standard precision (SP) and XP docking of 3L8P crystal are both higher than those from 2WQB, indicating that the discrimination power of molecular docking based on 3L8P is much higher

  • Targeted intervention of ANG/Tie-2 signaling pathway in preliminary vessels represents a promising strategy for the treatment of various life-threatening diseases

Read more

Summary

Introduction

Targeting VEGF signaling have been under clinical assessment, and several of them, such as sunitinib (Sutent) and sorafenib (Nexavar), have been approved by the Food and Drug Administration (FDA)[4,9,10]. Hundreds of molecules were found effect in inhibiting Tie-2 activity including some FDA-approved tyrosine kinase inhibitors, several of which showed quite good inhibitory activity in nM level Though these inhibitors may not be developed specially towards Tie-2, they are still helpful in understanding the binding patterns of Tie-2 and offer clues for the design of selective Tie-2 inhibitors. In VS campaign, clustering analysis can be performed based on the top ranked compounds to maximize the molecular diversity of the candidates This practice may have a pronounced influence on the overall hit rates. The information provided and the active compounds identified in this work can help to guide the design and discovery of novel and potent inhibitors of Tie-2 as well as the structure-based VS of other protein targets

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call